Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Prime Medicine, Inc. (PRME – Research Report) today and set a price target of $21.00. The company’s shares opened today at $16.63.
According to TipRanks, Harrison is a 5-star analyst with an average return of 7.9% and a 53.46% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and Editas Medicine.
Prime Medicine, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $23.75.
See the top stocks recommended by analysts >>
The company has a one-year high of $21.73 and a one-year low of $14.52. Currently, Prime Medicine, Inc. has an average volume of 264.1K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRME in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs.
Read More on PRME:
